Please login to the form below

Not currently logged in
Email:
Password:

JAK inhibitor

This page shows the latest JAK inhibitor news and features for those working in and with pharma, biotech and healthcare.

Gilead and Galapagos JAK contender scores in RA trial

Gilead and Galapagos JAK contender scores in RA trial

The first JAK inhibitor on the market is Pfizer’s Xeljanz (tofacitinib) and already earns in excess of $1bn a year in RA revenues. ... Analysts are predicting a showdown between filgotinib and AbbVie’s rival, upadacitinib, as the next decisive event

Latest news

More from news
Approximately 7 fully matching, plus 64 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2018

    Royalty monetisation. 230. Jiangsu Hengrui Medicine/Arcutis. SHR0302, selective JAK inhibitor, for dermatology disorders (currently p2 for RA in China). ... This acquisition brings tucatinib, an oral tyrosine kinase inhibitor that is highly selective for

  • Deal Watch table for December 2014 Deal Watch table for December 2014

    Company acquisition. 3, 500. Astellas/ J&J. ASP015K, an oral JAK inhibitor for RA (p3). ... ONT-380 (ARRY-380), oral, reversible and selective small molecule HER2 inhibitor (p1).

  • Pharma deals during September 2013 Pharma deals during September 2013

    cancer, and AT13387, a second generation HSP90 inhibitor for the treatment of prostate and lung cancers. ... antibody (MAb) Actemra and Pfizer's JAK inhibitor Xeljanz.

  • Pharma deals during October 2012 Pharma deals during October 2012

    Heading the deal table is the $945m licence between Astellas Pharma and Janssen for the exclusive rights outside Japan to ASP015K, an oral janus kinase (JAK) inhibitor that is undergoing phase ... 60. ‡‡ Ethical Oncology Science / Servier.

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Streaming Well

Streaming Well is a healthcare focused, award-winning video production company which operates in the US and Europe....

Latest intelligence

Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...
Ali Frederic Ben-Amor
Tackling a formidable foe
Ali Frederic Ben-Amor tells how Merck is taking the fight to multiple sclerosis...
Geoff
Cancer care – the power of new technologies
With patient numbers set to soar, how can we make a difference?...

Infographics